English  |  正體中文  |  简体中文  |  Items with full text/Total items : 55217/89514 (62%)
Visitors : 10718800      Online Users : 28
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/41440


    Title: Fine-tuning risperidone dosage for acute schizophrenia : clinical determinants
    Authors: Lane, Hsien-yuan;Chang, Yue-cune;張玉坤;Chiu, Chih-chiang;Lee, Sue-hong;Lin, Cher-yeang;Chang, Wen-ho
    Contributors: 淡江大學數學學系
    Keywords: Diagnosis subtype;Disorganized subtype;Dose;Gender;Risperidone;Chinese
    Date: 2004-04
    Issue Date: 2010-01-28 07:34:22 (UTC+8)
    Publisher: Springer
    Abstract: Rationale

    Risperidone doses for acute schizophrenia were rather high in most recent studies.

    Objectives

    We tested a hypothesis that fine-tuning risperidone dosage to relieve side effects still yields efficacy. Clinical factors influencing the dosing were also determined.

    Methods

    One hundred and forty-six schizophrenia inpatients with acute exacerbation entered a prospective, 6-week, repeated measures study. Risperidone doses were titrated to 6 mg/day (if tolerable) within 7 days, but were lowered thereafter if adverse reactions appeared. Efficacy and safety were measured biweekly.

    Results

    Forty-eight patients tolerated the 6-mg/day target dose well, while the other 98 received lower final doses (mean±SD=3.4±0.9 mg/day) to curtail adverse effects. At endpoint, 64.3% of the low-dose patients and 43.8% of the high-dose subjects responded to treatment [≥20% reduction in the Positive and Negative Syndrome Scale (PANSS) total score] (P=0.018). In detail, the low-dose individuals were significantly superior in percentage changes in the PANSS total and general-subscale scores at endpoint. The low-dose group also tended to improve more (albeit statistically insignificantly) in the PANSS positive and negative subscales and other efficacy measures. Compared to the patients with undifferentiated subtype, those with disorganized subtype received higher dosage by 0.90 mg/day, after controlling for other variables (P=0.008). Paranoid subtype was similar to undifferentiated subtype in drug doses. Patients with longer illness duration also showed a trend to use higher dosage (P=0.078).

    Conclusions

    These findings suggest that dosage adjustment to diminish side effects does not compromise risperidone response and that disorganized patients and perhaps patients with longer illness duration are prone to receive larger doses.
    Relation: Psychopharmacology 172(4), pp.393-399
    DOI: 10.1007/s00213-003-1685-6
    Appears in Collections:[Graduate Institute & Department of Mathematics] Journal Article

    Files in This Item:

    File SizeFormat
    index.html0KbHTML59View/Open

    All items in 機構典藏 are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback